🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Allist Pharmaceuticals clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Allist Pharmaceuticals as lead sponsor. Synced 26 Sep 2026
13Current trials
9Recruiting now
13Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Allist Pharmaceuticals is the lead sponsor of 13 current clinical trials in our China register. 9 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Glecirasib, Carboplatin and Furmonertinib. The most-studied condition is NSCLC.

ClinicalTrials.gov trials by status

  • Recruiting969%
  • Active, closed431%

Trials by phase

  • Phase 3646%
  • Phase 1/2431%
  • Phase 2215%
  • Phase 118%
01

Clinical trials sponsored by Allist Pharmaceuticals

13 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
NCT06970639 · ClinicalTrials.gov ↗ · NSCLC Patients With Brain Metastasis
Phase 3 Recruiting 2024-09 China
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
NCT06008288 · ClinicalTrials.gov ↗ · KRAS P.G12C, Pancreatic Cancer, Solid Tumor
Phase 2 Recruiting 2023-10 China
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
NCT06956001 · ClinicalTrials.gov ↗ · EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 3 Recruiting 2024-11 China
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
NCT05276726 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer
Phase 1/2 Recruiting 2022-08 China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06955988 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1 Recruiting 2025-03 China
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy(FIRMOST)
NCT07010419 · ClinicalTrials.gov ↗ · NSCLC, Adjuvant Treatment
Phase 3 Recruiting 2025-05 China
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
NCT04853342 · ClinicalTrials.gov ↗ · Non-small Cell Lung Carcinoma
Phase 3 Recruiting 2021-06 China
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205 · ClinicalTrials.gov ↗ · KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer
Phase 1/2 Recruiting 2022-04 China
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410 · ClinicalTrials.gov ↗ · Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
Phase 3 Recruiting 2024-08 China
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
NCT05466149 · ClinicalTrials.gov ↗ · NSCLC
Phase 2 Active, closed 2022-09 China
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
NCT05009329 · ClinicalTrials.gov ↗ · NSCLC, Solid Tumor
Phase 1/2 Active, closed 2021-07 China
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
NCT05194995 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
Phase 1/2 Active, closed 2022-02 China
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)
NCT03787992 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Drug: Gefitinib
Phase 3 Active, closed 2019-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Allist Pharmaceuticals trials

13 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Allist Pharmaceuticals trials

19 conditions
NSCLC3Solid Tumor2KRAS P.G12C2Non-small Cell Lung Cancer2NSCLC Patients With Brain Metastasis1Pancreatic Cancer1EGFR1NSCLC (Advanced Non-small Cell Lung Cancer)1Locally Advanced or Metastatic Non-small Cell Lung Cancer1Adjuvant Treatment1Non-small Cell Lung Carcinoma1Advanced Colorectal Cancer1Small Intestinal Cancer1Appendiceal Cancer1Colorectal Cancer1Pancreatic Ductal Carcinoma1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer1Advanced Non-squamous Non-small-cell Lung Cancer1Metastatic Non-squamous Non Small Cell Lung Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China139

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in NSCLC

SponsorTrials
Sichuan University3
Tubulis2
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)2
TYK Medicines2
Jiangsu Cancer Institute & Hospital2
Ellipses Pharma1
Eikon Therapeutics1
Shanghai Huaota Biopharmaceutical1
Monte Rosa Therapeutics1
Wen-zhao ZHONG1

Sponsors with the most current trials registered for this condition.

06

Questions about Allist Pharmaceuticals trials

How many clinical trials does Allist Pharmaceuticals sponsor?

Allist Pharmaceuticals is the lead sponsor of 13 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Allist Pharmaceuticals trials recruiting?

Yes. 9 of its 13 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Allist Pharmaceuticals testing?

Its current trials name 13 drugs and biologicals as interventions. The most frequent are Glecirasib (6), Carboplatin (3), Furmonertinib (3), Cisplatin (2) and JAB-3312 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.